Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impai...
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study
About this item
Full title
Author / Creator
Publisher
United States: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
United States: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and severe renal impairment (RI).
In this 1-year, double-blind study, 133 patients with type 2 diabetes (HbA(1c) 7.0-10.0%) and severe RI (estimated glomerular filtration rate [eGFR] <30 mL/min...
Alternative Titles
Full title
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3554278
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3554278
Other Identifiers
ISSN
0149-5992
E-ISSN
1935-5548
DOI
10.2337/dc12-0706
